Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Up 18.9% in April

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 8,556,479 shares, an increase of 18.9% from the March 31st total of 7,193,959 shares. Based on an average daily trading volume, of 1,392,898 shares, the days-to-cover ratio is currently 6.1 days. Currently, 3.3% of the shares of the company are short sold.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. UBS Group assumed coverage on shares of Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $19.00 price target on the stock. Truist Financial boosted their price target on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Large investors have recently made changes to their positions in the business. Kemnay Advisory Services Inc. acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth $26,000. Federated Hermes Inc. increased its position in shares of Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after acquiring an additional 2,168 shares in the last quarter. Spire Wealth Management increased its position in shares of Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after acquiring an additional 1,023 shares in the last quarter. Transamerica Financial Advisors LLC increased its position in shares of Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after acquiring an additional 2,460 shares in the last quarter. Finally, Comerica Bank increased its position in shares of Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after acquiring an additional 1,957 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX traded down $0.02 on Friday, hitting $12.85. The company’s stock had a trading volume of 545,793 shares, compared to its average volume of 2,345,511. Amneal Pharmaceuticals has a 12-month low of $7.02 and a 12-month high of $15.42. The company has a market capitalization of $4.04 billion, a price-to-earnings ratio of 33.81 and a beta of 1.32. The stock has a 50 day moving average of $12.87 and a 200-day moving average of $12.61.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.11. Amneal Pharmaceuticals had a net margin of 4.53% and a negative return on equity of 276.67%. The business had revenue of $723.00 million for the quarter, compared to the consensus estimate of $709.79 million. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.950-1.050 EPS and its Q1 2026 guidance at 0.270-0.270 EPS. Sell-side analysts expect that Amneal Pharmaceuticals will post 0.92 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.